ARGXのPER（株価収益率）は？

ARGENX NV ADR（ARGX）は現在PER 21.03倍で取引されています。

ARGXのROE（自己資本利益率）は？

ARGENX NV ADRのROEは30.84%です。

ARGXの配当利回りは？

ARGENX NV ADRの配当利回りは0.00%です。

ARGXの品質スコア（Quality Score）は？

当社のAIはARGXの総合財務品質を100点中62点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

ARGXは今が買い時ですか？

当社AIのタイミングスコアは100点中71点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

ARGXはどのセクターに属しますか？

ARGENX NV ADRはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）

ARGX (NASDAQ) 株価分析 | ARGENX NV ADR

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-06-30)

ARGX AI Analysis Summary

Our AI summary for ARGX: ARGENX NV ADR (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 21.03, ROE of 30.84%, a dividend yield of 0.00%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 71/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ARGX

ARGENX NV ADR

US:NASDAQ STOCK Healthcare >> Biotechnology News 94

USD 853.82

-18.76 (-2.15%) Day Change

Watchlist Portfolio Compare Chart

21.03

P/E

0.00

D/E

30.8%

ROE

25.9%

ROA

0.00%

Div Yield

ARGENX NV ADR
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 853.82 Price -18.76 (-2.15%) Day Change	NEWS SCORE: 94

ARGX, ファンダメンタルスコアはok ( ファンダメンタル = 62) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

62 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: ROEの伸びが低い
平均ROEが低い
ROAの伸びが低い
NPMの伸びが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...

Deepscope 分析

51%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	94
Magic Formula Rank by ROA	701
Magic Formula Rank by ROE	701
Magic Formula Rank by ROIC	622
Price	853.82
PBV / Sector	6.49 / 5.20
Earning Per Share	40.60

PE / Sector	21.03 / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	253.24 M GREAT
Average 1W Daily Value	231.19 M GREAT

Timing Factors

14%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

64%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	30.73 / 98.71 GREAT
NPM Average (%) / Sector	-19.39 / -1,721.76
NPM Change Average (%) / Sector	-90.89 / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	25.87 / 27.02 GREAT
ROA Average (%) / Sector	5.01 / -368.17
ROA Change Average (%) / Sector	-73.35 / 5,404.12
ROE (%) / Sector	30.84 / 3.47 GREAT
ROE Average (%) / Sector	6.24 / 6.51
ROE Change Average (%) / Sector	-72.65 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

登録情報

Analyze Date	2026-08-01 07:59:29
Symbol	ARGX
Name	ARGENX NV ADR
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	62.56 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	54,589.47 / 9,903.94

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Laarderhoogtweg 25, Amsterdam, Netherlands, 1101 EB

Phone: 31 10 703 8441

Website: https://argenx.com

Employees: 1,863

Sector: Healthcare >> Biotechnology

Description: argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.